Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19580820 | 0.86 | RAB9A (0.49) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL19600735 | 0.86 | HRH3 (0.54) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL9210265 | 0.84 | HRH3 (0.69) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL3767435 | 0.84 | HRH3 (0.68) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL9204223 | 0.83 | HRH3 (0.73) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL9210226 | 0.82 | HRH3 (0.72) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132267 | 0.81 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132220 | 0.81 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132223 | 0.81 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132837 | 0.81 | HRH3 (0.61) | HRH3NPC1RAB9AKMT2ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HRH3 3784/4885NPC1 1813/4885RAB9A 4010/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HRH3 3784/4885NPC1 1813/4885RAB9A 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.